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ABSTRACT 
The aim of this multicenter, randomized, double-blind, 8-week study was to compare the 
antidepressant efficacy and tolerability of mirtazapine and venlafaxine in the treatment of 
hospitalized patients with DSM-IV diagnosis of severe depressive episode with melancholic 
features. Patients with a baseline score of > or = 25 on the 17-item Hamilton Rating Scale for 
Depression (HAM-D-17) were randomly assigned to receive treatment with either mirtazapine 
(N = 78, 15-60 mg/day) or venlafaxine (N = 79, 75-375 mg/day, twice a day) in a rapid up-
titration schedule. Efficacy was assessed with the Montgomery-Asberg Depression Rating Scale 
(MADRS), HAM-D-17, and Clinical Global Impression scale, and quality of life was assessed with 
the Quality of Life, Enjoyment, and Satisfaction Questionnaire and Quality of Life in Depression 
Scale. Tolerability was assessed with the Utvalg for Kliniske Undersogelser (UKU) side effect 
scale and by reporting adverse events. Both drugs were effective in reducing overall symptoms 
of depression, showing substantial reductions in group mean MADRS scores (-20.1 for 
mirtazapine and -17.5 for venlafaxine) and HAM-D-17 scores (-17.1 for mirtazapine and -14.6 
for venlafaxine) at the end of the treatment. Although not statistically significant, at all 
assessment times higher percentages of patients treated with mirtazapine were classified as 
responders (> or =50% reduction) on the HAM-D (at endpoint, 62% vs. 52%) and MADRS (at 
endpoint: 64% vs. 58%). Likewise were the percentages of remitters (HAM-D score < or =7; 
MADRS score < or =12) also higher in the mirtazapine group. A statistically significant 
difference favoring mirtazapine was found on the HAM-D Sleep Disturbance factor at all 
assessment points (p < or = 0.03). Both treatments were well tolerated. Although slightly more 
subjects treated with mirtazapine reported at least one adverse event, a statistically significantly 
higher percentage of patients treated with venlafaxine (15.3%) than mirtazapine (5.1%) 
dropped out because of adverse events (p = 0.037). Quality of life improved in both treatment 
groups. In this study, treatment with mirtazapine resulted in a trend toward more responders 
and remitters than treatment with venlafaxine and in significantly fewer dropouts as a result of 
adverse events. 
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The term melancholia denotes a variety of conditions, and it has most often been used as a term 
for depression. Its use was readopted in DSM-III as an operationally defined subtype of a major 
depressive disorder.1 The usage continued in DSM-III-R2 and DSMIV,3 which currently uses the 
“melancholic features” specifier for the major depressive episode or bipolar I or II major 
depressive episode. The essential features are anhedonia and loss of reactivity to usually 
pleasurable stimuli. Other common features are diminished or absent mood reactivity, 
psychomotor changes observable by others, excessive guilt, anorexia or weight loss, early 
morning awakenings, and a depressed mood that is worse in the morning. Several studies 
suggested that tricyclic antidepressants (TCAs), and in particular the dual-acting clomipramine, 
are superior to selective serotonin reuptake inhibitors (SSRIs) in treating melancholic 
depression (for a review, see Amsterdam1). However, TCAs are often not as well tolerated as the 
SSRIs and the newer agents. Venlafaxine, a dual-acting serotonin and noradrenaline reuptake 
inhibitor (SNRI), has been demonstrated more effective than placebo2 and fluoxetine3 in treating 
hospitalized patients with melancholic depression, and this also suggests the superiority of dual-
acting antidepressants in these patients. The efficacy of mirtazapine (Remeron, N.V. Organon, 
Oss, The Netherlands), a dual-acting noradrenergic and specific serotonergic antidepressant 
(NaSSA), is established in placebo-controlled studies,4 and it demonstrated superiority over 
fluoxetine5, citalopram,6 and paroxetine7 in patients who were moderately to severely 
depressed. The aim of this study was to compare the efficacy and tolerability of mirtazapine and 
venlafaxine in hospitalized patients who were severely depressed with melancholic features, in a 
randomized, double-blind, 8-week study. 
Methods 
This study was a multicenter, randomized, double-blind comparison of mirtazapine and 
venlafaxine, performed in 23 centers in France, 4 centers in Belgium, 2 centers in Denmark, and 
4 centers in The Netherlands in the period between January 1997 and July 1999. Patients 
meeting inclusion and exclusion criteria were recruited from psychiatric inpatient populations. 
The ethics committee of each participating center approved the study. Each participating patient 
gave written informed consent before starting any study-related activity. The study was 
conducted in compliance with the current revision of the Declaration of Helsinki, International 
Conference for Harmonization guidelines, good clinical practice, and current regulatory 
regulations in the countries where the study was conducted.  
Male and female hospitalized patients between 18 and 65 years old who fulfilled DSM-IV criteria 
for a severe depressive episode (296.23 or 296.33) with melancholic features according to the 
DSM-IV checklist, had a total score of ≥25 on the 17-item Hamilton Rating Scale for Depression 
(HAM-D-17)8 at the start and end of the placebo washout period, and who were willing to give 
informed consent in writing were eligible for participation in this study.  
Reasons for exclusion included a current depressive episode of more than 12 months’ duration, 
more than two previous episodes of major depression that did not respond to adequate 
antidepressant therapy, lack of response to at least two antidepressant therapies given for at 
least 6 weeks during the current episode, a reduction of ≥25% in the HAM-D-17 score during the 
placebo washout period, a major suicide risk, a history of or presence of a bipolar disorder, 
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depressive disorder not otherwise specified, depression with psychotic features, depression 
with atypical features, depression with postpartum onset, depression with catatonic features, or 
organic mental disorders. Subjects with a present condition of anxiety disorders (according to 
DSM-IV), eating disorders (specifically, anorexia nervosa and bulimia nervosa), epilepsy or a 
history of a seizure disorder or of a treatment with anticonvulsant medication for epilepsy or 
seizures, alcohol intoxication or substance abuse (according to DSM-IV), schizophrenia, or other 
psychotic disorders were excluded. Female patients were also excluded if they were pregnant, 
lactating, or of childbearing potential and not taking adequate contraceptive measures. Presence 
of any clinically meaningful nonstable physical disease or abnormal findings on physical 
examination or laboratory testing were reasons for exclusion. The following treatments must 
have been stopped within the indicated intervals before the start of active study medication: 
electroconvulsive therapy (3 months, and not for the actual episode), neuroleptics and depot 
neuroleptics for antipsychotic purpose (2 months) or neuroleptics as anxiolytics (4 days), 
fluoxetine (4 weeks), benzodiazepines (patients receiving oxazepam with a minimum dose of 50 
mg/day, without a washout period), monoamine oxidase inhibitors (2 weeks), moclobemide (3 
days), mirtazapine (current episode), venlafaxine (current episode), and other psychotropic 
drugs (1 week).  
Subjects were not permitted to use antihypertensive medication such as guanethidine, 
guanoxan, clonidine, prazosin, or α-methyldopa. Any psychotropic medications other than the 
trial medication were not allowed in the protocol; sedative drugs (including sedative 
antihistaminics), anticholinergic drugs, and sympathomimetic drugs (including epinephrine) 
were not allowed, nor was concurrent psychotherapy for the treatment of depression or formal 
psychotherapy. The following concomitant medications were allowed: medication for the mild 
physical illness other than defined in the exclusion criteria; in case of sleeping problems, a 
maximum of 20 mg of zolpidem; and, in case anxiety symptoms were a reason for 
discontinuation, short-acting benzodiazepines (e.g., oxazepam, maximally 50 mg/day, not more 
than three times per week, and not on the day before an assessment).  
After a 3- to 7-day placebo washout period, patients were randomized to receive treatment with 
either mirtazapine or venlafaxine orally for 8 weeks, prepared as indistinguishable capsules, 
according to a centrally prepared randomization list. Packaging was performed by use of a 
double-dummy technique. The dosing regimen for both drugs was in line with the standard 
labeling. To match differences in morning and evening administration, subjects treated with 
mirtazapine were to take a placebo capsule in the morning. The dose of mirtazapine was 15 
mg/day on days 1 and 2, 30 mg/day on days 3 through 5, and 45 mg/day on days 6 through 8. 
From day 9 onward, the daily dose could be increased to 60 g/day, depending on the clinical 
response. The dose of venlafaxine was 75 mg/day, twice a day, during days 1 and 2; 150 mg/day 
during days 3 through 5; and 225 mg daily from day 6 onward, until trial completion. This dose 
could be increased to 300 or 375 mg (depending on the clinical response) daily from day 9 to 
day 56.  
Assessments were performed at screening, at baseline (day 0), and at weeks 1, 2, 4, 6, and 8 of 
active treatment (or on premature withdrawal). Efficacy was assessed with the Montgomery-
Åsberg Depression Rating Scale (MADRS),9 HAM-D-17, and Clinical Global Impression (CGI) 
scales (Severity of Illness and Global Improvement).10 Patient-rated Quality of Life, Enjoyment, 
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and Satisfaction Questionnaires (QLESQ)11 and Quality of Life in Depression Scales (QLDS)12 
were used in local languages and completed at weeks 2, 4, and 8. Secondary efficacy parameters, 
such as percentages of HAM-D-17 and MADRS responders, were defined as the percentage of 
patients with a ≥50% decrease from baseline scores. HAM-D-17 and MADRS remitters were 
defined as patients with a total score of ≤7 and a total score of ≤12, respectively. Tolerability 
was assessed by the Utvalg for Kliniske Undersogelser (UKU) side effect scale13 and by the 
registration of adverse events at baseline and at weeks 1, 2, 4, 6, and 8. Vital signs were 
measured at the same assessment points, as were laboratory variables at baseline and at the last 
visit. All adverse events were coded by using the dictionary terms from the World Health 
Organization adverse reaction terminology (1997 version).14 
All investigators were trained in using the rating scales 1 month before the start of the trial and 
once during the trial to achieve a maximum consistency between and within raters. All subjects 
were to be instructed by the investigators on the use of the Quality of Life questionnaire. 
Sample-size calculations were based on the assumption that at least 65 patients per group 
(minimal size of the intent-to-treat [ITT] group) would complete 4 weeks of treatment. With this 
sample size, the trial would have a 90% power to detect a difference of 35% versus 10% (two-
sided testing at p=0.05) and a power of 80% to detect a significance level of 5%.  
Efficacy analyses were based on the ITT patient sample, thus including all randomly assigned 
subjects who received at least one dose of study medication and had at least one postbaseline 
efficacy assessment, by using the last observation carried forward method. Changes from 
baseline in the total MADRS and HAM-D-17 scores, HAMD factor scores, CGI Severity of Illness, 
QLESQ, and QLDS scores were statistically analyzed by means of an analysis of variance 
(ANOVA). The estimates of treatment difference and corresponding two-sided 95% confidence 
intervals were based on the additive two-way ANOVA with factors treatment and country. 
Secondary efficacy variables, such as percentages of HAM-D-17 and MADRS responders 
(patients with a ≥50% decrease from baseline scores), HAM-D-17 remitters (total score of ≤7), 
and MADRS remitters (total score of ≤12) were analyzed with the Cochran-Mantel-Haenszel 
test,15 adjusting for country. The CGI Global Improvement scores were analyzed by means of the 
Wilcoxon test, adjusting for country, but for the communication of results, an ANOVA model was 
used. The primary time point for treatment comparison was the endpoint assessment, with 
week-4 assessment as the second in order of importance.  
Tolerability and safety data were calculated for all patients who were randomized to treatment 
and received at least one dose of blinded study medication. Adverse events are presented in 
frequency tables. The numbers of patients with “new” or “worsened” symptoms on the UKU 
scale (as compared with baseline) were compared between the two treatment groups by use of 
the Fisher exact test. All analyses were performed with SAS Version 6.12 or higher (SAS 
Institute, Cary, NC). 
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One hundred seventy-eight subjects were screened to participate in the trial. Of these, 157 were 
randomly assigned to either treatment group and took at least one dose of study medication 
(mirtazapine, N = 78; venlafaxine, N = 79). Seventy-seven patients treated with mirtazapine and 
75 with venlafaxine were included in the ITT group.  
Both groups were well matched at baseline with respect to the demographic characteristics and 
mean group scores on the rating scales used in the study (Table 1).  
TABLE 1. Demographic and disease characteristics at baselinea 
 
 
aHAM-D-17, 17-item Hamilton Rating Scale for Depression; MADRS, Montgomery-Åsberg Depression Rating Scale; 
CGI, Clinical Global Impression Scale; QLESQ, Quality of Life, Enjoyment and Satisfaction Questionnaire; QLDS, Quality 
of Life in Depression Scale; UKU, Utvalg for Kliniske Undersogelser side effect scale. 
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MEAN DAILY DOSES OF STUDY MEDICATION 
In the ITT population, the mean daily dose (±SD) throughout the whole study period (including 
the 9-day rapid up-titration) was 49.5 ±8.3 mg/day of mirtazapine and 255.0 ± 59.8 mg/day of 
venlafaxine. 
DROPOUTS 
More patients treated with mirtazapine (76.9%) than venlafaxine (64.6%) completed the study. 
Statistically significantly more patients treated with venlafaxine (15.3%) than mirtazapine 
(5.1%) dropped out from the study because of intolerable adverse events (p = 0.037; Table 2). 
TABLE 2. Number (%) of dropouts in either treatment group (all randomized patients) 
 
 
p = 0.037, venlafaxine versus mirtazapine. 
EFFICACY 
The group mean MADRS and HAM-D-17 scores decreased from baseline at all assessment points 
in both treatment groups, indicating a substantial improvement in overall depressive symptoms. 
On the MADRS, although not statistically significantly different, the magnitudes of reductions 
were somewhat larger with mirtazapine at all assessment times. At week 4, the estimate of 
treatment difference of 2.3 points in favor of mirtazapine reached the level of clinical 
relevance16 (95% confidence interval [CI]: -5.9 to 1.2; p = 0.195) (Fig. 1). Similar results were 
seen on the HAM-D-17, with a somewhat larger reduction with mirtazapine at all assessments 
and a trend in favor of mirtazapine16 at week 4 (estimate of treatment difference, -2.6; 95% CI,    
-5.1 to 0.0; p = 0.055) and week 8 (estimate of treatment difference, -2.1; 95% CI, -5.0 to 0.8; p = 
0.154) (Fig. 2). Both treatments resulted in similar reductions from baseline in HAM-D anxiety 
and retardation factors at all assessment points. However, on the sleep disturbance factor, 
treatment with mirtazapine resulted in statistically significantly larger changes from baseline 
than treatment with venlafaxine from week 1 onward. This was maintained at all assessment 
times throughout the study (Table 3) (week 1, p = 0.022; weeks 2–8, p ≥ 0.001).  
In addition, treatment with mirtazapine resulted in higher percentages of responders and 
remitters. Although this difference was not statistically significant, at all assessment points 
during the 8-week treatment period, a higher percentage of responders and remitters was 
observed in the mirtazapine group than in the venlafaxine group, with both the MADRS and the 
HAM-D-17 criteria (Fig. 3).  
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CGI Severity of Illness scores decreased in both treatment groups, indicating that the illness 
became less severe. In line with the results for primary efficacy variables, larger magnitudes of 
reduction were observed in the mirtazapine group (Table 3). Subjects in both groups became 
more satisfied with their quality of life, as assessed with both QLESQ and QLDS (Table 3). 
 
FIG. 1. Changes from baseline (BL) in mean group MADRS scores during 8 weeks of treatment with either mirtazapine 
(15–60 mg/day; N = 73 evaluable patients) or venlafaxine (75–375 mg/day; N = 71 evaluable patients). Baseline 
scores: mirtazapine group, 34.6; venlafaxine group, 33.9. 
 
FIG. 2. Changes from baseline (BL) in mean group HAM-D-17 scores during 8 weeks of treatment with either 
mirtazapine (15–60 mg/day; N =77 evaluable patients) or venlafaxine (75–375 mg/day; N =75 evaluable patients). 
Baseline scores: mirtazapine group, 29.5; venlafaxine group, 28.9. 
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Slightly more patients treated with mirtazapine (N = 58; 74.4%) than with venlafaxine (N = 52; 
65.8%) reported at least one adverse event (Table 4). Discontinuation rates resulting from 
intolerable adverse events have been described previously. One patient in the venlafaxine group 
committed suicide on study day 5.  
In general, incidences of reported adverse events were similar in both treatment groups. The 
observed differences between mirtazapine and venlafaxine were predictable (Table 5). In the 
mirtazapine group, the most frequently reported adverse events were complaints of weight 
increase (by 10.3% of patients), followed by dry mouth (9.0%), headache (7.7%), sleepiness 
(7.7%), nausea (6.4%), nervous tension (5.1%), sedation (5.1%), and accommodation 
disturbances (5.1%). In the venlafaxine group, increased sweating was reported by 19.0% of 
patients, followed by constipation (15.2%), headache (11.4%), nausea (10.1%), orthostatic 
hypotension (6.3%), and decreased salivation (6.3%).  
For the following side effects described in the UKU scale, the incidences differed more than 10% 
between the mirtazapine and the venlafaxine group, respectively: nausea (15.8% vs. 27.0%), 
constipation (17.1% vs. 31.1%, p = 0.056), orthostatic dizziness (14.5% vs. 27.7%), increased 
tendency to sweat (15.8% vs. 35.1%, p ≤ 0.05), weight loss (21.1% vs. 39.2%, p ≤ 0.05), and 
weight gain (57.9% vs. 36.5%, p ≤ 0.05).  
No clinically relevant changes in blood pressure, heart rate, or laboratory variables were 
registered during the study. In the mirtazapine group, endpoint change from baseline in the 
body weight was 2.0 ± 3.7 kg, and in the venlafaxine group it was -0.5 ± 2.9 kg. This difference 
was statistically significant ( p = 0.001). 
TABLE 3. Efficacy variables at endpoint: estimates of treatment differences, corresponding 95% 
confidence intervals, and p values (ITT group, LOCF analysis)a 
 
aITT, intent to treat; LOCF, last observation carried forward; CI, confidence interval; HAM-D-17, 17-item Hamilton 
Rating Scale for Depression; MADRS, Montgomery-Åsberg Depression Rating Scale; CGI, Clinical Global Impression; 
QLESQ, Quality of Life, Enjoyment, and Satisfaction Questionnaire; QLDS, Quality of Life in Depression Scale. 
bFavorable for mirtazapine. 
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FIG. 3. Percentages of MADRS and HAM-D-17 responders (top) and remitters (bottom) as a function of time. 
Responders were defined as patients with at least a 50% decrease from baseline scores. MADRS and HAM-D-17 
remitters were defined as patients with a total score of ≤12 and a total score of ≤7, respectively. 
TABLE 4. Percentage of adverse events reported in ≥5% of patients in either treatment groupa 
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TABLE 5. The UKU symptoms with an incidence of ≥10% in either treatment group, or a statistically 
significant difference between the groupsa 
 
aValues presented are percentages. UKU, Utvalg for Kliniske Undersogelser side effect scale. 
bp ≤ 0.05 (Fisher exact test). 
cp = 0.056 (Fisher exact test). 
Discussion 
This was the first study comparing the antidepressant efficacy and tolerability of mirtazapine 
and venlafaxine in hospitalized patients diagnosed with DSM-IV severe depressive episode with 
melancholic features. Both drugs were effective for improving patients’ overall symptoms of 
depression and their quality of life. Although no statistically significant differences were 
registered between the treatments on primary efficacy measures, mirtazapine was consistently 
associated with somewhat larger magnitudes of change from baseline on both the HAM-D-17 
and MADRS, and this difference was clinically relevant at week 4 (for both HAM-D-17 and 
MADRS) and endpoint (for HAM-D-17) (a difference of ≥2 points on either HAM-D-17 or 
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MADRS).16 In addition, also not statistically significant, there was a consistent advantage for 
mirtazapine in percentages of patients classified as responders and remitters, by use of both the 
HAM-D-17 and MADRS criteria. Mirtazapine produced statistically significant improvements 
from baseline in HAM-D sleep disturbance factor at all assessments.  
In this study, the mean doses were 49.5 ± 8.3 mg/day for mirtazapine and 255.0 ± 59.8 mg/day 
for venlafaxine over the complete 8-week period, including the 9-day rapid up-titration. These 
high dosages were in line with the dosages used in similar trials with these kinds of patients.2, 3, 5 
More patients treated with mirtazapine (76.9%) than venlafaxine (64.6%) completed the study. 
Although more of the patients treated with mirtazapine reported at least one adverse event 
compared with those treated with venlafaxine, statistically significantly more patients treated 
with venlafaxine (15.3%) than with mirtazapine (5.1%) dropped out because of intolerable 
adverse events.  
In terms of reported adverse events and side effects registered on the UKU scale, the tolerability 
profiles of both drugs observed in this study did not differ from those previously reported.4, 17 
Studies in hospitalized patients with severe depression and melancholia are rarely conducted. 
There are data showing that patients with severe depression respond less well to antidepressant 
therapy than those with moderate depression,18 whereas melancholia was generally held to be 
responsive to antidepressant treatment.19, 20  
Another drawback to studies with severe depression is that they do not always differentiate 
between complete or partial responders when baseline scores are high. Individuals who are 
severely depressed with a baseline HAM-D score of, e.g., 30 would still be symptomatic, even 
with a 50% reduction, at the end of the study.21 Nevertheless, a large majority of the currently 
available body of evidence regarding the efficacy of different classes of antidepressants in 
melancholic depression is derived from post hoc analyses.1 Among new antidepressants, 
venlafaxine has demonstrated its antidepressant efficacy over placebo in treatment of 
hospitalized patients with major depression and melancholia,2 whereas dual-acting 
antidepressants, such as the TCA clomipramine,22, 23 the SNRI venlafaxine,3 and the NaSSA 
mirtazapine,5–7 have been consistently shown to outperform single-acting SSRIs in this patient 
population.  
In this patient population, which is characterized by poor sleep and early awakening, the 
statistically significant improvements in the HAM-D sleep disturbance factor with mirtazapine 
throughout the study may have important clinical implications. On the basis of the 
pharmacologic profile, a difference in sexual dysfunction in favor of mirtazapine was expected as 
well. However, the fact that the population in this study was hospitalized patients with severe 
melancholic depression may explain that no differences in sexual functioning between the two 
treatments were observed.  
In conclusion, this study shows that both of the dualacting antidepressants mirtazapine and 
venlafaxine are effective for treating hospitalized patients with severe depression and 
melancholic features. Short-term treatment with mirtazapine seemed better tolerated, and this 
was demonstrated by the significantly higher dropout rate caused by adverse events in the 
venlafaxine group.  
Published in : Journal of Clinical Psychopharmacology (2001), vol. 21, n°4, pp. 425–431 
DOI:10.1097/00004714-200108000-00010 










Published in : Journal of Clinical Psychopharmacology (2001), vol. 21, n°4, pp. 425–431 
DOI:10.1097/00004714-200108000-00010 





1. Amsterdam JD. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J 
Psychopharmacol 1998;12[suppl B]:S99–S111. 
2. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major 
depression and melancholia. J Clin Psychiatry 1995;56:450–8. 
3. Clerc GE, Ruimy P, Verdeau-Paillès J, et al. A double-blind comparison of venlafaxine and fluoxetine in 
patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study 
Group. Int Clin Psychopharmacol 1994;9:139–40. 
4. Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. Drugs 1999;57:607–31. 
5. Wheatley DP, van Moffaert M, Timmerman L, et al. Mirtazapine: efficacy and tolerability in comparison 
with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine 
Study Group. J Clin Psychiatry 1998;59:306–12. 
6. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a 
double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study 
Group. Int Clin Psychopharmacol 1999;14:329–37. 
7. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin 
Psychiatry 2000;61:656–63. 
8. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62. 
9. Montgomery SA, Åsberg M. A new depression rating scale designed to be sensitive to change. Br J 
Psychiatry 1979;134:382–9. 
10. Guy W. ECDEU assessment manual for psychopharmacology, revised. Department of Health, Education, 
and Welfare, Publication no. (ADM) 76–338. Rockville, MD: National Institutes of Mental Health, 
1976:218–222. 
11. Endicott J, Nee J, Harrison W, et al. Quality of Life, Enjoyment and Satisfaction Questionnaire: a new 
measure. Psychopharmacol Bull 1993;29:321–6. 
12. Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health 
Policy 1992;22:307–19. 
13. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. Acta Psychiatr Scand 
1987;76[suppl 334]:1–100. 
14. World Health Organization. Adverse reactions terminology (WHOART). Geneva: World Health 
Organization, 1997. 
15. Koch GC, Carr J. Categorical data analysis. In: Berry DA, ed. Statistical methodology in pharmaceutical 
sciences. New York: Marcel Dekker, 1990:389–473. 
16. Montgomery SA. Clinically relevant effect sizes in depression. Eur Neuropsychopharmacol 
1994;4:283–4. 
17. Dierick M. A review of the efficacy and tolerability of venlafaxine. Eur Psychiatry 1997;12[suppl 
4):S307–S313. 
Published in : Journal of Clinical Psychopharmacology (2001), vol. 21, n°4, pp. 425–431 
DOI:10.1097/00004714-200108000-00010 




18. Kocsis JH, Croughan JL, Katz MM, et al. Response to treatment with antidepressants of patients with 
severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry 
1990;147:621–4. 
19. Keller MB. Diagnostic issues and clinical course of unipolar illness. Review of psychiatry. Washington, 
DC: American Psychiatric Press, 1988;7:188–212. 
20. Prien RF. Somatic treatment of unipolar depressive disorder. Review of psychiatry. Washington, DC: 
American Psychiatric Press, 1988;7:213–34. 
21. Hirschfeld RMA. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with 
TCAs. J Clin Psychiatry 1999;60:326–35. 
22. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with 
clomipramine. A controlled multicentre study. Psychopharmacology 1986;90:131–8. 
23. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker 
antidepressant effect than clomipramine in a controlled multicenter study. Danish University 
Antidepressant Group. J Affect Disord 1990;18:289–99. 
  
 
